Growth Hormone Treatment in Children: Review of Safety and Efficacy

Pediatric Drugs

Volumn 6, Issue 2, 2004, Pages 93-106

  Harris, Mark ^a   Hofman, Paul L ^a   Cutfield, Wayne S ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GONADORELIN DERIVATIVE; HUMAN GROWTH HORMONE;

BODY COMPOSITION; BODY GROWTH; BODY HEIGHT; CHRONIC KIDNEY FAILURE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GLUCOSE METABOLISM; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; HUMAN; MUSCULOSKELETAL SYSTEM; PRADER WILLI SYNDROME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SMALL FOR DATE INFANT; TURNER SYNDROME; BODY MASS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CYSTIC FIBROSIS; DRUG RESPONSE; GROWTH ACCELERATION; HORMONAL THERAPY; INSULIN RESISTANCE; JUVENILE RHEUMATOID ARTHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS;

CHILD; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; TREATMENT OUTCOME;

EID: 1842763599     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200406020-00003     Document Type: Review

References (137)

1. Barker DJ, Hales CN, Fall CH, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidemia (syndrome X): relation to reduced fetal growth. Diabetologica 1993; 36: 62-7
2. Chatelain P, Job JC, Blanchard J, et al. Dose-dependent catch-up growth after 2 years of growth hormone treatment in intrauterine growth retarded children. J Clin Endocrinol Metab 1994; 78: 1454-60
3. Job JC, Chaussain JL, Job B, et al. Follow-up of three years of treatment with growth hormone and of one post-treatment year, in children with severe growth retardation of intrauterine onset. Pediatr Res 1996; 39: 354-9
4. Heptulla RA, Boulware SD, Caprio S, et al. Decreased insulin sensitivity and compensatory hyperinsulinemia after hormone treatment in children with short stature. J Clin Endocrinol Metab 1997; 82: 3234-8
5. Botero D, Danon M, Brown RS. Symptomatic non-insulin dependent diabetes mellitus during therapy with recombinant human growth hormone. J Pediatr 1993; 123: 590-2
6. Hofman PL, Cutfield WS, Robinson EM, et al. Insulin resistance in short children with intra-uterine growth retardation. J Clin Endocrinol Metab 1997; 82: 402-6
7. Smith TR, Elmendorf JS, David TS, et al. Growth hormone-induced insulin resistance: role of the insulin receptor, IRS-1, GLUT-1 and GLUT-4. Am J Physiol 1997; 272: E1071-9
8. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement therapy: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998; 83: 382-95
9. Bengtsson BA, Johannsson G, Shalet SM, et al. Treatment of growth hormone deficiency in adults. J Clin Endocrinol Metab 2000; 85: 933-42
10. Eiholzer U, Gisin R, Weinmann C, et al. Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance. Eur J Pediatr 1998; 157: 368-77
11. Carrel AL, Myers SE, Whitman BY, et al. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J Pediatr 1999; 134: 215-21
12. Rosenfeld RG, Albertsson-Wikland K, Cassorla F, et al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995; 80: 1532-40
13. Chaler E, Belgorosky A, Maceiras M, et al. Between-assay differences in serum growth hormone (GH) measurements: importance in the diagnosis of GH deficiency in childhood. Clin Chem 2001; 47: 1735-8
14. Georges P, Roger M, Carton F, et al. Comparison of immunoreactivity of five pharmaceutical hGH preparations and WHO standard (66/217) by means of two monoclonal sandwich assays. Horm Res 1990; 33: S3-18
15. Marin G, Domene HM, Barnes KM, et al. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab 1994; 79: 537-41
16. Veldhuis JD, Liem AY, South S, et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 1995; 80: 3209-22
17. Cacciari E, Tassoni P, Parisi G, et al. Pitfalls in diagnosing impaired growth hormone secretion: retesting after replacement therapy of 63 patients defined as growth hormone deficient. J Clin Endocrinol Metab 1992; 74: 1284-9
18. Rimoin DL, Merimee TJ, Rabinowitz D, et al. Genetic aspects of clinical endocrinology. Recent Prog Horm Res 1968; 24: 365-437
19. Ranke MB. A note on adults with growth hormone deficiency. Acta Paediatr Scand Suppl 1987; 331: 80-2
20. van der Werff ten Bosch JJ, Bot A. Growth of males with idiopathic hypopituitarism without growth hormone treatment. Clin Endocrinol 1990; 32: 707-17
21. Burns EC, Tanner JM, Preece MA, et al. Final height and pubertal development in 55 children with idiopathic growth hormone deficiency, treated for between 2 and 15 years with human growth hormone. Eur J Pediatr 1981; 137: 155-64
22. Lenko HL, Leisti S, Perheentupa J. The efficacy of growth hormone in different types of growth failure: an analysis of 101 cases. Eur J Pediatr 1982; 138: 241-9
23. Rikken B, Massa C, Wit JM. Final height in a large cohort of Dutch patients with growth hormone deficiency treated with growth hormone. Horm Res 1995; 43: 135-7
24. Milner RD, Russel-Fraser T, Brook CG, et al. Experience with human growth hormone in Great Britain: the report of the MRC working party. Clin Endocrinol 1979; 11: 15-38
25. Cutfield WS, Lindberg A, Chatelain P, et al. Final height following growth hormone treatment of idiopathic growth hormone deficiency in KIGS. In: Ranke MB, Wilton P, editors. Growth hormone therapy in KIGS: 10 years' experience. Heidelberg: Johann Ambrosius Barth Verlag, 1999: 93-109
26. Severi F. Final height in children with growth hormone deficiency. Horm Res 1995; 43: 138-40
27. Blethen S, Baptista J, Kuntze J, et al. Adult height in GH (GH) -deficient children treated with biosynthetic GH. J Clin Endocrinol Metab 1997; 82: 418-20
28. August GP, Lippe BM, Blethen SL, et al. Growth hormone treatment in the United States: demographic and idiopathic features of 2331 children. J Pediatr 1990; 116: 899-903
29. Wilton P, Lindberg A. Isolated growth hormone deficiency and multiple pituitary deficiencies: patient characteristics and 12-month treatment results. KIGS Biannual Report 1996; 2 (14): 15-24
30. Cutfield WS, Jonsson P, Bagewitz A. Demographic trends: 1987-1996. KIGS Biannual Report 1997; 1 (15): 3-12
31. Longas AF, Mayayo E, Labarta JI. Congenital growth hormone deficiency arising from central cranial malformations: experience in KIGS. In: Ranke MB, Wilton P, editors. Growth hormone therapy in KIGS: 10 years' experience. Heidelberg: Johann Ambrosius Barth Verlag, 1999: 135-46
32. Hellstrom A, Chatelain P, Cutfield WS, et al. Septo-optic dysplasia: experience with 151 cases in KIGS. In: Ranke MB, Wilton P, editors. Growth hormone therapy in KIGS: 10 years' experience. Heidelberg: Johann Ambrosius Barth Verlag, 1999: 147-57
33. Price DA. Growth hormone treatment in children with craniopharyngioma in KIGS. In: Ranke MB, Wilton P, editors. Growth hormone therapy in KIGS: 10 years' experience. Heidelberg: Johann Ambrosius Barth Verlag, 1999: 189-98
34. Ranke MB, Price DA. Growth hormone treatment in children with malignant cranial tumours in KIGS. In: Ranke MB, Wilton P, editors. Growth hormone therapy in KIGS: 10 years' experience. Heidelberg: Johann Ambrosius Barth Verlag, 1999: 159-74
35. Stahnke N. Growth hormone treatment in children in remission from leukaemia and lymphoma in KIGS. In: Ranke MB, Wilton P, editors. Growth hormone therapy in KIGS: 10 years' experience. Heidelberg: Johann Ambrosius Barth Verlag, 1999: 175-88
36. Adan L, Sainte-Rose C, Souberbielle JC, et al. Adult height after growth hormone (GH) treatment for GH deficiency due to cranial irradiation. Med Pediatr Oncol 2000; 34: 14-9
37. Brauner R, Rappaport R, Prevot C, et al. A prospective study of the development of growth hormone deficiency in children given cranial irradiation and its relation to statural growth. J Clin Endocrinol Metab 1989; 68: 346-51
38. Ranke MB, Pfluger H, Rosendahl W, et al. Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur J Pediatr 1983; 141: 81-8
39. Lyon AJ, Preece MA, Grant DB. Growth curve for girls with Turner syndrome. Arch Dis Child 1985; 60: 932-5
40. Saenger P. Turner syndrome. N Engl J Med 1996; 23: 1749-54
41. Rao E, Weiss B, Fukami M, et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 1997; 16: 54-63
42. Ross JL, Long LM, Loriaux DL, et al. Growth hormone secretory dynamics in Turner syndrome. J Pediatr 1985; 106: 202-6
43. Rosenfeld RG, Hintz RL, Johanson AJ, et al. Methionyl human growth hormone and oxandrolone in Turner syndrome: preliminary results of a prospective randomized trial. J Pediatr 1986; 109: 936-43
44. Carel JC, Mathivon L, Gendrel C, et al. Near normalization of final height with adapted doses of growth hormone in Turner syndrome. J Clin Endocrinol Metab 1998; 83: 1462-6
45. Rosenfeld RG, Attie KM, Frane J. et al. Growth hormone therapy of Turner syndrome: beneficial effect on adult height. J Pediatr 1998; 132: 319-24
46. Sas TC, de-Muinck-Keizer-Schrama SM, Stijen T, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab 1999; 84: 4607-12
47. Cacciari E, Mazzanti L. Final height of patients with Turner syndrome treated with growth hormone (GH): indications for GH therapy alone at high doses and late estrogen therapy. Italian Study Group for Turner syndrome. J Clin Endocrinol Metab 1999; 84: 4510-5
48. Rochiccioli P, Battin J, Bertrand AM, et al. Final height in Turner syndrome patients treated with growth hormone. Horm Res 1995; 44: 172-6
49. Van den Broeck J, Massa G, Attanasio A, et al. Final height after long-term growth hormone treatment in Turner syndrome: European Study Group. J Pediatr 1995; 127: 729-35
50. Nilsson KO, Albertsson-Wikland K, Alm J, et al. Improved final height in girls with Turner syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab 1996; 81: 635-40
51. Haeusler G, Schmitt K, Blumel P, et al. Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height. Acta Paediatr 1996; 85: 1408-14
52. Reiter EO, Blethen SL, Baptista J, et al. Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner syndrome. J Clin Endocrinol Metab 2001; 86: 1936-41
53. Karlberg J, Schaefer F, Hennicke M, et al. European Study Group for nutritional treatment of chronic renal failure in childhood: early age-dependent growth impairment in chronic renal failure. Pediatr Nephrol 1996; 10: 283-7
54. Schaefer F, Seidel C, Binding A, et al. Pubertal growth in chronic renal failure. Pediatr Res 1990; 28: 5-10
55. Schaefer F, Mehls O. Endocrine and growth disorders. In: Barratt TM, Avner ED, Harmon W, editors. Pediatric nephrology. 4th ed. Baltimore (MD): Williams & Wilkins, 1998: 1197-230
56. Tejani A, Sullivan K. Long-term follow-up of growth in children post transplantation. Kidney Int 1993; 44: 56-8
57. Rizzoni G, Ehrich JH, Brunner FP, et al. Combined report on regular dialysis and transplantation of children in Europe. Pediatr Nephrol 1990; 4: 548-51
58. Fine RN, Kohaut E, Brown D, et al. Long-term treatment of growth-retarded children with chronic renal insufficiency with recombinant human growth hormone. Kidney Int 1996; 49: 781-5
59. Haffner D, Schaefer F, Nissel R, et al. Effect of growth hormone treatment on the adult height of children with chronic renal failure. N Engl J Med 2000; 343: 923-30
60. Haffner D, Schaefer F. Does recombinant growth hormone improve adult height in children with chronic renal failure. Semin Nephrol 2001; 21: 490-7
61. Wuhl E, Haffner D, Schaefer F, et al. Short children on dialysis treatment respond less to growth hormone than patients with chronic renal failure prior to dialysis. Pediatr Nephrol 1996; 10: 294-8
62. Fine RN, Sullivan EK, Tejani A. The impact of recombinant human growth hormone treatment on final adult height. Pediatr Nephrol 2000; 14: 679-81
63. Mehls O, Berg U, Broyer M, et al. Chronic renal failure and growth hormone treatment: review of the literature and experience in KIGS. In: Ranke MB, Wilton P, editors. Growth hormone therapy in KIGS: 10 years' experience. Heidelberg: Johann Ambrosius Barth Verlag, 1999: 327-40
64. Hokken-Koelega ACS, Mulder P, De Jong R, et al. Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency. Pediatr Nephrol 2000; 14: 701-6
65. Donaldson MDC. Growth hormone therapy in Turner syndrome: current uncertainties and future strategies. Horm Res 1997; 48 Suppl. 5: 35-44
66. Ranke MB, Lindberg A, Chatelain P, et al. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. J Clin Endocrinol Metab 2000; 85: 4212-8
67. Ranke MB, Lindberg A, Cowell CT, et al. Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab 2003; 88: 125-31
68. Karlberg J, Albertsson-Wikland K. Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res 1995; 38: 733-9
69. Botero D, Lifshitz F. Intrauterine growth retardation and long-term effects on growth. Curr Opin Pediatr 1999; 11: 340-7
70. Hediger ML, Overpeck MD, Maurer KR, et al. Infants and young children born small or large for gestational age: findings from the third national health and nutrition examination survey. Arch Pediatr Adolesc Med 1998; 152: 1225-31
71. Tanner JM, Whitehouse RH, Hughes PCR, et al. Effect of human growth hormone treatment for 1 to 7 years on the growth of 100 children with growth hormone deficiency, low birth weight, inherited smallness, Turner's syndrome, and other complaints. Arch Dis Child 1971; 46: 745-82
72. Grunt JA, Enriquez AR, Daughaday WH, et al. Acute and long-term responses to hGH in children with idiopathic small-of-dates dwarfism. J Clin Endocrinol Metab 1972; 35: 157-68
73. de Waal WJ, Hokken-Koelega ACS, Stijen TH, et al. Endogenous and stimulated growth hormone secretion, urinary growth hormone excretion, and plasma IGF-I and IGF-II levels in prepubertal children with short stature after intrauterine growth retardation. Clin Endocrinol (Oxf) 1994; 41: 621-30
74. Stanhope R, Ackland F, Hamill G, et al. Physiological growth hormone secretion and response to growth hormone treatment in children with short stature and intra-uterine growth retardation. Acta Paediatr Scand Suppl 1989; 349: 47-52
75. Boguszewski CL, Rosberg S, Albertsson-Wikland K. Spontaneous 24-hour growth hormone profiles in prepubertal small for gestational age children. J Clin Endocrinol Metab 1995; 80: 2599-606
76. Boguszewski CL, Jansson C, Boguszewski M, et al. Increased proportion of circulating non-22-kilodalton growth hormone isoforms in short children: a possible mechanism for growth failure. J Clin Endocrinol Metab 1997; 82: 2944-9
77. Boguszewski M, Albertsson-Wikland K, Aronsson S, et al. Growth hormone treatment of short children born small-for-gestational-age: the Nordic multicentre trial. Acta Paediatr 1998; 87: 257-63
78. de Zegher F, Maes M, Gargosky SE, et al. High-dose growth hormone treatment of short children born small-for-gestational-age. J Clin Endocrinol Metab 1996; 81: 1887-92
79. de Zegher F, Du Caju MV, Heinrichs C, et al. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years. J Clin Endocrinol Metab 1999; 84: 1558-61
80. Sas T, de Waal W, Mulder P, et al. Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab 1999; 84: 3064-70
81. Tanner JM, Lejarraga H, Cameron N. The natural history of the Silver-Russell syndrome: a longitudinal study of thirty-nine cases. Pediatr Res 1975; 9: 611-23
82. Donaldson MDC, Chu CE, Cooke A, et al. The Prader-Willi syndrome. Arch Dis Child 1994; 70: 58-63
83. Holm VA, Cassidy SB, Butler MG, et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993; 91: 398-402
84. Thacker M, Hainline B, Dennis-Feezle L, et al. Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency. Horm Res 1998; 49: 216-20
85. Eiholzer U, Stutz K, Weinmann C, et al. Low insulin, IGF-I, and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome. Eur J Pediatr 1998; 157: 890-3
86. Costeff H, Holm VA, Ruvalcaba R, et al. Growth hormone secretion in Prader-Willi Syndrome. Acta Paediatr Scand 1990; 79: 1059-62
87. Vanderscheuren-Lodeweyckx M. The effect of simple obesity on growth and growth hormone. Horm Res 1993; 40: 23-30
88. Jabbar M, Pugliese M, Fort P, et al. Excess weight and precocious pubarche in children: alterations of the adrenocortical hormones. J Am Coll Nutr 1991; 10: 289-96
89. Forbes GB. Influence of nutrition. In: Forbes GB, editor. Human body composition: growth, aging, nutrition, and activity. New York: Springer-Verlag, 1987: 209
90. Bray GA, Dahms WT, Swerdloss RS, et al. The Prader-Willi syndrome: a study of 40 patients and a review of the literature. Medicine 1983; 62: 59-80
91. Ghigo E, Mazza E, Corrias A, et al. Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children. Metabolism 1989; 38: 631-3
92. Beccaria L, Benzi F, Sanzari A, et al. Impairment of growth hormone responsiveness to growth hormone releasing hormone and pyridostigmine in patients affected with Prader-Labhart-Willi syndrome. J Endocrinol Invest 1996; 19: 687-92
93. Corrias A, Bellone J, Beccaria L, et al. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli: Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. J Endocrinol Invest 2000; 23: 84-9
94. Lindgren AC, Hagenas L, Muller J, et al. Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report. Acta Pediatr Suppl 1997; 423: 60-2
95. Hauffa BP. One year results of growth hormone treatment of short stature in Prader-Willi syndrome. Acta Pediatr Suppl 1997; 423: 63-5
96. Lindgren AC, Ritzen EM. Five years of growth hormone treatment in children with Prader-Willi syndrome. Acta Pediatr Suppl 1999; 433: 109-11
97. Carrel AL, Myers SE, Whitman BY, et al. Benefits of long-term growth hormone therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002; 87: 1581-5
98. Eiholzer U, l'Allemand D. Growth hormone normalizes height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy. Horm Res 2000; 53: 185-92
99. Brismar TB, Lindgren AC, Ringertz H, et al. Total body bone mineral measurements in children with Prader-Willi syndrome: the influence of the skull's bone mineral content per area (BMA) and of height. Pediatr Radiol 1998; 28: 38-42
100. Ansell BM, Bywaters EGL. Growth in Still's disease. Ann Rheum Dis 1956; 15: 295-319
101. Hyams JS, Carey DE. Corticosteroids and growth. J Pediatr 1988; 113: 249-54
102. Falcini F, Taccetti G, Trapani S, et al. Growth retardation in juvenile chronic arthritis patients treated with steroids. Clin Exp Rheumatol 1991; 9 Suppl. 6: 37-40
103. Bechtold S, Ripperger P, Muhlbayer D, et al. Growth hormone therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone. J Clin Endocrinol Metab 2001; 86: 5737-44
104. Rizza RA, Mandarino LJ, Gerich JE. Cortisol insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a receptor defect of insulin action. J Clin Endocrinol Metab 1982; 54: 131-8
105. Saenger P, Attie KM, DiMartino-Nardi J, et al. Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature. J Clin Endocrinol Metab 1998; 83: 3115-20
106. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation, patient registry 1998 annual data report. Bethesda (MD): Cystic Fibrosis Foundation, 1999
107. National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) and Cystic Fibrosis Foundation. Workshop on nutrition in cystic fibrosis. Bethesda (MD): CF Foundation Press, 1993
108. Sheperd R, Cooksley WGE, Cooke WDD. Improved growth and clinical, nutritional, and respiratory changes in response to nutritional therapy in cystic fibrosis. J Pediatr 1980; 97: 351-7
109. Huseman CA, Colombo JL, Brooks MA, et al. Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients. Pediatr Pulmonol 1996; 22: 90-5
110. Hardin DS, Ellis KJ, Dyson M, et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. J Pediatr 2001; 139: 636-42
111. Hutler M, Schnabel D, Staab D, et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Med Sci Sports Exerc 2002; 34: 567-72
112. Moran A, Hardin DS, Rodman D, et al. Diagnosis screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999; 45: 61-73
113. Cohen P, Bright GM, Rogol AD, et al. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 2002; 87: 90-8
114. Ranke MB, Lindberg A, Chatelain P, et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. J Clin Endocrinol Metab 1999; 84: 1174-83
115. Kristrom B, Jansson C, Rosberg S, et al. Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-1) and IGF-binding protein-3 in short children with various GH secretion capacities: Swedish Study Group for GH Treatment. J Clin Endocrinol Metab 1997; 82: 2889-98
116. Hibi I, Tananka T, Tanae A, et al. The influence of gonadal function and the effect of gonadal suppression treatment on final height in growth hormone (GH) treated GH-deficient children. J Clin Endocrinol Metab 1989; 69: 221-6
117. Sklar CA. Growth and neuroendocrine dysfunction following therapy for childhood cancer. Pediatr Clin North Am 1997; 44: 489-503
118. Saggese G, Federico G, Barsanti S, et al. The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study. J Clin Endocrinol Metab 2001; 86: 1900-4
119. Cutfieid W. KIGS (Pharmacia & Upjohn International Database): adverse events report No. 8. KIGS biannual report 1996; 2 (14): 35-43
120. Wilton P. Adverse events during growth hormone treatment: 10 years' experience in KIGS, a pharmacoepidemiological survey. In: Ranke MB, Wilton P, editors. Growth hormone therapy in KIGS: 10 years' experience. Heidelberg: Johann Ambrosius Barth Verlag, 1999: 349-64
121. Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996; 81: 1704-10
122. Rawlins MD, Breckenridge AM, Wood SM. National adverse drug reaction reporting: a silver jubilee. Adverse Drug React Bull 1989; 138: 516-9
123. Gravholt CH, Juul S, Naeraa RW, et al. Morbidity in Turner syndrome. J Clin Epidemiol 1998; 51: 147-58
124. Walker J, Chaussain JL, Bougneres PF. Growth hormone treatment of children with short stature increases insulin secretion but does not impair glucose disposal. J Clin Endocrinol Metab 1989; 69: 253-8
125. Hindmarsh PC, Pringle PJ, Di Silvio L, et al. Effects of three years of growth hormone therapy in short normal children. Acta Pediatr Scand Suppl 1990; 366: 6-12
126. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth hormone treatment. Lancet 2000; 355: 610-3
127. Mercola KE, Cline MJ, Golde DW. Growth hormone stimulation of normal and leukemic human T-lymphocyte proliferation in vitro. Blood 1981; 58: 337-40
128. Cullen KJ, Yee D, Sly WS, et al. Insulin-like growth factor expression and function in human breast cancer. Cancer Res 1990; 50: 48-53
129. Lawson Wilkins Pediatric Endocrine Society Writing Committee. Growth hormone treatment and neoplasia: coincidence or consequence? J Clin Endocrinol Metab 2002; 87: 5351-2
130. Weiss M, Sutton L, Marcial V, et al. The role of radiation therapy in the management of childhood craniopharyngioma. Int J Radiat Oncol Biol Phys 1989; 17: 1313-21
131. Swerdlow AJ, Higggins CD, Adlard P, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002; 360: 273-7
132. Salomon F, Cuneo RC, Hesp P, et al. The effects of treatment with recombinant growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-803
133. Saenger P. Metabolic consequences of growth hormone treatment in paediatric practice. Horm Res 2000; 53 Suppl. 1: 60-9
134. Loder RT, Wittenberg B, De Silva G. Slipped capital femoral epiphysis associated with endocrine disorders. J Pediatr Orthop 1995; 15: 349-56
135. Harris WR. The endocrine basis for slipping of the upper femoral epiphysis. J Bone Joint Surg 1950; 32-B: 169-75
136. Cowell CT, Dietsch S. Adverse events during growth hormone therapy. J Pediatr Endocrinol Metab 1995; 8: 243-52
137. Wang ED, Drummond DS, Dormans JP, et al. Scoliosis in patients treated with growth hormone. J Pediatr Orthop 1997; 17: 708-11